Nanomics Biotechnology Information

Nanomics Biotech, founded by national leaders in innovation and entrepreneurship, focuses on a high-throughput proteomics platform to discover protein biomarkers. With over 80% of the team from the University of Chicago, the company holds national recognition as a technology-oriented enterprise with numerous patent applications. Our Proteonano™ platform can detect 1500-5000 plasma proteins covering 2000 signaling pathways, supporting research institutes, pharmaceutical companies, and medical enterprises. We offers the 5000 Plex proteomics custom service for biomarker discovery, spatial proteomics, and protein quantification. Additionally, Nanomics has launched collaborative initiatives, including the Nanomics Center of Excellence (NCOE) and the Nanomics Proteomics Advancement Initiative (PAI). Nanomics operates a 1000-square-meter laboratory with a class I medical device production license, housing 50 ultra-multiplex high-throughput proteomics platforms processing 100,000 samples annually. Nanomics has excelled in biomarker discovery for neurological and cardiac diseases, along with drug efficacy evaluation. Collaborative projects are ongoing with research institutions, universities, service companies, and pharmaceutical enterprises nationwide.